Opinion

Video

Bladder Cancer: Treatment Options and Managing Adverse Effects

Author(s):

Axel Merseburger, MD, PhDM. Carmen Mir, MD, PhD

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Related Videos
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Viktor Grünwald, MD, PhD
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Related Content
Benjamin L. Maughan, MD, PharmD
June 7th 2024

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Benjamin L. Maughan, MD, PharmD
June 6th 2024

Advancements With Combination Therapies in RCC Usher in New Questions

Jack Khouri, MD
November 9th 2023

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

Jens Hoeppner, FAChirg, FACS, MD
June 5th 2024

Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC

Toni Choueiri, MD, of Dana-Farber Cancer Institute
June 3rd 2024

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC